Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-162
Last updated

Report documents

  1. Extract of dossier assessment

    Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 442 kB, EN, PDF
    Download file : Extract of dossier assessment (PDF-Dokument, 442 kB, EN, PDF)

  2. Dossier assessment

    Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF-Dokument, 617 kB, DE, PDF
    Download file : Dossier assessment (PDF-Dokument, 617 kB, DE, PDF)

Dossier assessment

Indication:

Adult patients with advanced or recurrent endometrial cancer whose disease has progressed during or after prior platinum-based chemotherapy at any stage of the disease, when surgery or radiation to cure the cancer is not an option for them

Result of dossier assessment:
  • Patients for whom doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: indication of a considerable added benefit
  • Patients for whom a therapy option other than doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: added benefit not proven

Press releases

Lenvatinib and pembrolizumab in endometrial cancer: patients live clearly longer

Compared with doxorubicin or paclitaxel, there is an indication of a considerable added benefit. An added benefit over other treatment options is not proven.
Press release

Additional information

Federal Joint Committee (G-BA)

2022-07-07 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A21-162
Commission
Commission awarded on 14.12.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-160
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-122
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Lenvatinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A19-19
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Lenvatinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-57
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Lenvatinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A16-63
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Lenvatinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)

    Project no.
    G15-06
    Last updated

    Status: Commission completed

  7. Addendum

    Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162

    Project no.
    A22-57
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page